BELIEVE study to assess Bimagrumab as treatment for obesity owenhaskins Jan 12, 2023 2 min read Versanis Bio, a clinical-stage biopharmaceutical company advancing novel therapeutics for cardiometabolic diseases, has announced that the BELIEVE Phase 2b study to assess the safety and efficacy of bimagrumab alone and in combination with semaglutide for the treatment of obesity has begun enrolling at sites in the US, Australia and New Zealand
GLP-1 medications work by interacting with specific receptors in the pancreas, digestive system, and brain, helping to increase feelings of fullness, slow gastric emptying, and reduce hunger cravings
| Concentration | BAC Water | Doses at 1.0mg | Doses at 2.4mg | |---------------|-----------|----------------|----------------| | 5mg/mL | 4.0mL | 20 doses | ~8 doses | | 2.5mg/mL | 8.0mL | 20 doses | ~8 doses | **Note:** At 4mL+ of liquid, ensure you have a large enough syringe (5mL or two separate 3mL draws) to transfer all the BAC water accurately
Patients with diabetes face increased UTI risk due to multiple factors including altered immune function and bladder emptying
If you inhibit glucagon secretion, you will also make blood glucose go down, because you then inhibit the production of glucose in the body
